Toggle menu

ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study

Start date:
March 2020
Co-ordinated by:
University of Oxford
Main trial site:
Royal Infirmary of Edinburgh, Western General Hospital, St John's Hospital

Infectious disease is the single biggest cause of death worldwide. New infectious agents, such as the SARS, MERS and other novel coronavirus’ require investigation to understand pathogen biology and pathogenesis in the host. Even for known infections, resistance to antimicrobial therapies is widespread, and treatments to control potentially deleterious host responses are lacking.

The ISARIC study aims to develop a mechanistic understanding of disease processes, so that risk factors for severe illness can be identified and treatments can be developed.

When patients are confirmed to have corona virus, the research team will ask them to participate into this study. The participant will be consenting to provide blood, urine and faecal samples throughout their admission at day 1, 3 and 9, with a final follow up completed at day 28.

Local PI

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Research Team

Rachel O'Brien

Lead Research Nurse

Nicky Freeman

Senior Research Nurse

Caroline Blackstock

AMU Senior Research Nurse

Emily Godden

Senior Research Nurse - Renal/Acute Medicine

Nicholas Fethers

Research Administrator

Michelle Coakley

Senior Research Nurse - Stroke/Neurosurgery

Julia Grahamslaw

Lead Research Nurse

More EMERGE Trials

Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.

Read more

IONA Study

Identification of Novel Psychoactive Substances (IONA)


Randomised Evaluation of COVID-19 Therapy

Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Read more


Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions